Group 1: Artisan Mid Cap Fund Performance - Artisan Mid Cap Fund's Investor Class fund ARTMX returned 8.80%, Advisor Class fund APDMX also posted a return of 8.80%, and Institutional Class fund APHMX returned 8.83% in Q3 2025, significantly outperforming the Russell Midcap Growth Index's return of 2.78% [1] - The strong performance was primarily driven by holdings in the health care sector [1] Group 2: DexCom, Inc. Overview - DexCom, Inc. (NASDAQ:DXCM) is a medical device company specializing in continuous glucose monitoring (CGM) systems, with a market capitalization of $25.651 billion as of October 15, 2025 [2] - The stock experienced a one-month return of -13.68% and a 52-week decline of 5.95% [2] Group 3: Investment Decisions Regarding DexCom, Inc. - Artisan Mid Cap Fund ended its investment in DexCom, Inc. due to operational challenges and strong competition from Abbott's FreeStyle Libre platform, despite recognizing the significant opportunity in Type 2 diabetes [3] - The fund opted to exit its position in favor of companies with higher conviction profit cycles and more compelling valuations [3] Group 4: DexCom, Inc. Financial Performance - For Q2 2025, DexCom, Inc. reported global revenue of $1.16 billion, reflecting a 15% growth compared to $1 billion in Q2 2024 [4] - Despite the growth potential, the company is not among the 30 most popular stocks among hedge funds, with 60 hedge fund portfolios holding its stock at the end of Q2 2025, unchanged from the previous quarter [4]